18 articles - From Friday Sep 30 2022 to Friday Oct 07 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Kidney Int |
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Consensus statements provide specific guidance on use of renin-angiotensin system inhibitors, metformin, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist. These areas of consensus provide clear direction for implementation of care to improve clinical outcomes of people with diabetes and CKD. |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Am J Kidney Dis |
A National Registry for People With All Stages of Kidney Disease: The National Kidney Foundation (NKF) Patient Network. The Network is positioned to become a national and international platform for real-world data that can inform the development of patient-centered research, care, and treatments. |
Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function. Severe anemia was common and strongly associated with lower eGFR and multiple adverse outcomes. Low iron test results were highly prevalent in those tested despite iron studies being checked infrequently. ESA use in non-dialysis CKD patients was uncommon. |
Association of Kidney Function Measures With Signs of Neurodegeneration and Small Vessel Disease on Brain Magnetic Resonance Imaging: The Atherosclerosis Risk in Communities (ARIC) Study. UACR and eGFR are associated with structural brain damage across different domains of etiology. eGFR- and UACR-related brain atrophy is not selective for regions typically affected by AD and LATE. Hence, AD or LATE may not be leading contributors to neurodegeneration associated with CKD. |
Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials. The absence of Hy's Law cases in REPRISE and the long-term extension trial support monthly liver enzyme monitoring during the first 18 months of tolvaptan exposure and every 3 months thereafter to detect and manage enzyme elevations as is recommended on the drug label. |
Deceased-Donor Acute Kidney Injury and Acute Rejection in Kidney Transplant Recipients: A Multicenter Cohort. In a large cohort of kidney recipients that were almost al induced with thymoglobulin, donor injury biomarkers were neither associated with graft failure and rejection, nor with a secondary outcome that included de novo DSA. These findings provide some reassurance that centers can successfully manage immunological complications using deceased-donor kidneys with AKI. |
Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease. Significant differences in ACU rates were observed across racial and ethnic groups in persons with prevalent GD, although many of these difference were explained by differences in socioeconomic status and disease severity. Measures to combat socioeconomic disadvantage in Black patients, and more effectively prevent and treat glomerular disease, are needed to reduce disparities in ACU, improve patient wellbeing, and reduce healthcare costs. |
| Clin J Am Soc Nephrol |
The Immune System and Idiopathic Nephrotic Syndrome. In fact, the unexpected efficacy of targeted therapeutic agents has provided important new insights into the pathogenesis of these diseases. Given the large number of drugs that are available to deplete or block specific cells and molecules within the immune system, a better understanding of the immunologic causes of idiopathic nephrotic syndrome may lead to better diagnostic and therapeutic approaches. |
| J Am Soc Nephrol |
Activation of Stimulator of Interferon Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases. The activation of the STING pathway acts as a mediator of disease progression in DKD and Alport syndrome. Targeting STING may offer a therapeutic option to treat glomerular diseases of metabolic and nonmetabolic origin or prevent their development, progression, or both. |
Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients. IFX induction therapy does not benefit recipients of kidney transplants from deceased donors on this IS regimen. Because the intervention unexpectedly increased rates of BK virus infections, our findings underscore the complexities of targeting peri-transplant inflammation as a strategy to improve KTx outcomes. |
| Kidney Int |
Associations between nephron number and podometrics in human kidneys. Thus, in this first study to report a direct correlation between the number of NSG and podometrics, we suggest that podocyte number is decreasing in NSG of individuals losing nephrons. However, another possible interpretation may be that more nephrons might protect against further podocyte loss. |
| Nephrol Dial Transplant |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Am J Kidney Dis |
| Nat Rev Nephrol |
Progress in xenotransplantation: overcoming immune barriers. Despite such modifications, immune responses to xenografts remain powerful and multi-faceted, involving innate immune components that do not attack allografts. Thus, the induction of innate and adaptive immune tolerance to prevent rejection while preserving the capacity of the immune system to protect the recipient and the graft from infection is desirable to enable clinical xenotransplantation. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Clin J Am Soc Nephrol |
Letters to the editors and authors’ replies
| J Am Soc Nephrol |